Development of an in-vivo active reversible butyrylcholinesterase inhibitor

Alzheimer’s disease (AD) is characterized by severe basal forebrain cholinergic deficit, which results in progressive and chronic deterioration of memory and cognitive functions. Similar to acetylcholinesterase, butyrylcholinesterase (BChE) contributes to the termination of cholinergic neurotransmis...

Descripción completa

Detalles Bibliográficos
Autores principales: Košak, Urban, Brus, Boris, Knez, Damijan, Šink, Roman, Žakelj, Simon, Trontelj, Jurij, Pišlar, Anja, Šlenc, Jasna, Gobec, Martina, Živin, Marko, Tratnjek, Larisa, Perše, Martina, Sałat, Kinga, Podkowa, Adrian, Filipek, Barbara, Nachon, Florian, Brazzolotto, Xavier, Więckowska, Anna, Malawska, Barbara, Stojan, Jure, Raščan, Irena Mlinarič, Kos, Janko, Coquelle, Nicolas, Colletier, Jacques-Philippe, Gobec, Stanislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175178/
https://www.ncbi.nlm.nih.gov/pubmed/28000737
http://dx.doi.org/10.1038/srep39495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175178/
https://www.ncbi.nlm.nih.gov/pubmed/28000737
http://dx.doi.org/10.1038/srep39495

Ejemplares similares